Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

Christian L Hvas; Mia Bendix; Anders Dige; Jens F Dahlerup; Jørgen Agnholt

doi:10.1080/08923973.2018.1469144

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

Christian L Hvas, Mia Bendix, Anders Dige, Jens F Dahlerup, Jørgen Agnholt

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

31 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. This review describes the hallmark immunobiology of Crohn's disease and ulcerative colitis as well as therapeutic targets and mechanisms of action for current, experimental, and future treatments in IBD. Conventional therapies include 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and methotrexate. Since 1997, monoclonal antibodies have gained widespread use. These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor α, interleukin (IL)-12, and IL-23, or anti-homing antibodies directed against α4β7 integrin. Emerging oral therapies include modulators of intracellular signal transduction such as Janus kinase inhibitors. Vitamin D may help to regulate innate and adaptive immune responses. Modulation of the intestinal microbiota, using live microorganisms (probiotics), substrates for the colonic microbiota (prebiotics), or fecal microbiota transplantation (FMT), is in development. Dietary supplements are in widespread use, but providing evidence for their benefit is challenging. Stem cell treatment and nervous stimulation are promising future treatments.

Original language	English
Journal	Immunopharmacology and Immunotoxicology
Volume	40
Issue	6
Pages (from-to)	446-460
Number of pages	15
ISSN	0892-3973
DOIs	https://doi.org/10.1080/08923973.2018.1469144
Publication status	Published - 2018

Keywords

Crohn’s disease
Inflammatory bowel disease
antibodies
fecal microbiota transplantation
monoclonal
ulcerative colitis

Access to Document

10.1080/08923973.2018.1469144

Cite this

@article{1ae1d721ea8643b9bb3276ee8b6db851,

title = "Current, experimental, and future treatments in inflammatory bowel disease: a clinical review",

abstract = "Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. This review describes the hallmark immunobiology of Crohn's disease and ulcerative colitis as well as therapeutic targets and mechanisms of action for current, experimental, and future treatments in IBD. Conventional therapies include 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and methotrexate. Since 1997, monoclonal antibodies have gained widespread use. These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor α, interleukin (IL)-12, and IL-23, or anti-homing antibodies directed against α4β7 integrin. Emerging oral therapies include modulators of intracellular signal transduction such as Janus kinase inhibitors. Vitamin D may help to regulate innate and adaptive immune responses. Modulation of the intestinal microbiota, using live microorganisms (probiotics), substrates for the colonic microbiota (prebiotics), or fecal microbiota transplantation (FMT), is in development. Dietary supplements are in widespread use, but providing evidence for their benefit is challenging. Stem cell treatment and nervous stimulation are promising future treatments.",

keywords = "Crohn{\textquoteright}s disease, Inflammatory bowel disease, antibodies, fecal microbiota transplantation, monoclonal, ulcerative colitis",

author = "Hvas, {Christian L} and Mia Bendix and Anders Dige and Dahlerup, {Jens F} and J{\o}rgen Agnholt",

year = "2018",

doi = "10.1080/08923973.2018.1469144",

language = "English",

volume = "40",

pages = "446--460",

journal = "Immunopharmacology and Immunotoxicology",

issn = "0892-3973",

publisher = "Informa Healthcare",

number = "6",

}

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. / Hvas, Christian L ; Bendix, Mia ; Dige, Anders et al.
In: Immunopharmacology and Immunotoxicology, Vol. 40, No. 6, 2018, p. 446-460.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Current, experimental, and future treatments in inflammatory bowel disease

T2 - a clinical review

AU - Hvas, Christian L

AU - Bendix, Mia

AU - Dige, Anders

AU - Dahlerup, Jens F

AU - Agnholt, Jørgen

PY - 2018

Y1 - 2018

N2 - Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. This review describes the hallmark immunobiology of Crohn's disease and ulcerative colitis as well as therapeutic targets and mechanisms of action for current, experimental, and future treatments in IBD. Conventional therapies include 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and methotrexate. Since 1997, monoclonal antibodies have gained widespread use. These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor α, interleukin (IL)-12, and IL-23, or anti-homing antibodies directed against α4β7 integrin. Emerging oral therapies include modulators of intracellular signal transduction such as Janus kinase inhibitors. Vitamin D may help to regulate innate and adaptive immune responses. Modulation of the intestinal microbiota, using live microorganisms (probiotics), substrates for the colonic microbiota (prebiotics), or fecal microbiota transplantation (FMT), is in development. Dietary supplements are in widespread use, but providing evidence for their benefit is challenging. Stem cell treatment and nervous stimulation are promising future treatments.

AB - Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. This review describes the hallmark immunobiology of Crohn's disease and ulcerative colitis as well as therapeutic targets and mechanisms of action for current, experimental, and future treatments in IBD. Conventional therapies include 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and methotrexate. Since 1997, monoclonal antibodies have gained widespread use. These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor α, interleukin (IL)-12, and IL-23, or anti-homing antibodies directed against α4β7 integrin. Emerging oral therapies include modulators of intracellular signal transduction such as Janus kinase inhibitors. Vitamin D may help to regulate innate and adaptive immune responses. Modulation of the intestinal microbiota, using live microorganisms (probiotics), substrates for the colonic microbiota (prebiotics), or fecal microbiota transplantation (FMT), is in development. Dietary supplements are in widespread use, but providing evidence for their benefit is challenging. Stem cell treatment and nervous stimulation are promising future treatments.

KW - Crohn’s disease

KW - Inflammatory bowel disease

KW - antibodies

KW - fecal microbiota transplantation

KW - monoclonal

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85063090960&partnerID=8YFLogxK

U2 - 10.1080/08923973.2018.1469144

DO - 10.1080/08923973.2018.1469144

M3 - Journal article

C2 - 29745777

SN - 0892-3973

VL - 40

SP - 446

EP - 460

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

IS - 6

ER -

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this